Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue  by Färber, P.M et al.
Recombinant Plasmodium falciparum glutathione reductase is inhibited
by the antimalarial dye methylene blue
P.M. Faºrbera;*, L.D. Arscottb, C.H. Williams Jr.b, K. Beckera, R.H. Schirmera
aBiochemie-Zentrum der Universitaºt Heidelberg, 5 OG, Im Neuenheimer Feld 328, D-69120 Heidelberg, Germany
bDepartment of Veterans A¡airs Medical Center and Department of Biological Chemistry, University of Michigan, Ann Arbor, MI 48105, USA
Received 21 November 1997; revised version received 7 January 1998
Abstract Plasmodium falciparum glutathione reductase
(PfGR) has emerged as a drug target against tropical malaria.
Here we report the expression of PfGR in Escherichia coli
SG5(DE3) and isolation procedures for this protein. Recombi-
nant PfGR does not differ from the authentic enzyme in its
enzymic properties, the turnover number being 9900 min31. The
dimeric flavoenzyme exhibits redox-dependent absorption spec-
tra; the single tryptophan residue (per 57.2 kDa subunit) is
strongly fluorescent. PfGR can be inhibited by the antimalarial
drug methylene blue at therapeutic concentrations; the Ki for
non-competitive inhibition is 6.4 WM. The sensitivity to
methylene blue is observed also at high ionic strength so that,
by analogy to human GR, analysis of crystalline enzyme-drug
complexes can be envisaged.
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1. Introduction
The clinical manifestations of tropical malaria are caused
by the multiplication and di¡erentiation of the protozoan
parasite Plasmodium falciparum in human erythrocytes. Ma-
larial parasites appear to be more sensitive to reactive oxygen
species than their host cells [1]. Inherited or drug-induced
de¢ciency of antioxidative erythrocyte enzymes such as glu-
cose-6-phosphate dehydrogenase [2,3] or glutathione reductase
[4,5] appear to protect from severe forms of falciparum ma-
laria. Glutathione reductase (GR), a dimeric £avoenzyme,
catalyses the reduction of glutathione disul¢de using NADPH
as a source of reducing equivalents: GSSG+NADPH+H =
2GSH+NADP. In the cytosol the enzyme maintains a
[GSH]/[GSSG] ratio of v 100. Glutathione in its reduced
form represents the most abundant intracellular non-protein
thiol. It is involved in a broad range of functions such as
protection of biomolecules from oxidative damage, detoxi¢ca-
tion of xenobiotics, and regulation of enzyme activity [6^9].
Both P. falciparum GR and human erythrocyte GR play
crucial roles for the intraerythrocytic growth of the parasite.
Human GR is a well characterized protein; the catalytic cycle
as well as the binding mode of drugs and other ligands have
been studied in great detail [4,6,7,10^12]. P. falciparum GR
(PfGR) has recently come into focus as a drug target. The
enzyme was puri¢ed from parasitized red blood cells but only
in Wg quantities [13]. To promote structural and functional
studies on this protein, the gene of PfGR was isolated [14].
As reported here, recombinant PfGR (rPfGR) was expressed,
puri¢ed and characterized, in particular as a target of meth-
ylene blue. This antimalarial compound, the ¢rst chemother-
apeutic agent to be successfully used in humans [15,16], is
known to interfere with the glutathione metabolism of para-
sitized erythrocytes [17].
2. Materials and methods
2.1. Materials and assay systems
E. coli SG5(DE3) was a kind gift of Dr. Sylke Muºller, Bernhard-
Nocht-Institute, Hamburg. Authentic PfGR (5 Wg from 1 g erythro-
cytes containing P. falciparum FBRC schizonts) was isolated as pre-
viously reported [13]. Recombinant human GR was puri¢ed and as-
sayed as described [12]. Expression vector pET22b+ was from
Novagen, Tth DNA polymerase from Boehringer Mannheim, and
restriction enzymes were from New England Biolabs. Superose 12
and 2P,5P-ADP-Sepharose were purchased from Pharmacia and
NADPH, GSSG, and IPTG from Biomol. Methylene blue (Fluka)
was used as a 10 mM stock solution in H2O. Vivaspin concentrator
units were from Greiner.
Protein in crude fractions was estimated by absorbance measure-
ments at 228.5 nm and 234.5 nm according to Ehresman et al. [18].
For puri¢ed PfGR in the Eox form, a solution of 1 mg/ml was found
to have an absorbance of 0.205 at 461 nm and of 1.43 at 275 nm.
These calibrations were performed by correlation with the absorbance
coe⁄cient of Eox which is 11.7 mM31 cm31 at 461 nm per 57.2 kDa
subunit (see Section 2.5).
2.2. Construction of the expression vector pG11
The fragments of the PfGR gene present in the plasmid constructs
pG1, pG2, pG3, and pG4 described in [14] were fused by consecutive
ligation into vector pT7 Blue (Novagen), taking advantage of unique
restriction sites for HincII, NheI, and SpeI in the ORF, to ¢nally
obtain construct pTG1-4. The 5P-end was obtained by 5P-RACE-
PCR on a Tth DNA polymerase-synthesized cDNA (T 6.1, see
[14]); the oligonucleotide primer G2 binds downstream the unique
HincII site (ATCGATCCAACGTTGACACACGTTC), whereas pri-
mer SN5 (ACGTAGCATGCCATATGGTTTACGATTTAATTG-
TAATTG) introduces SphI and NdeI restriction sites juxtaposed to
the start codon. The PCR product was digested with SphI and HincII
and ligated into pT1-4, resulting in the complete ORF of PfGR in the
plasmid pTG1-5. To remove the 3P-non-translated region of the
cDNA, pTG1-5 was digested with StyI and SacI and recircularized
by ligation of the hybridized oligonucleotides TGATGGATGAAAT-
GACTCGAGGAGCT and CACCCTCGAGTCATTTCATC, there-
by introducing an XhoI site upstream the SacI site. From this con-
struct, pTG, the complete ORF was excised by a NdeI-XhoI digest
and inserted into plasmid pET22b+, resulting in pG11 which encodes
the protein of 500 residues (N-terminal Met+499 residues [14]) under
the control of a T7 RNA polymerase promoter. The plasmid was then
introduced into E. coli SG5(DE3), a GR-de¢cient strain transformed
with phage DE3 to allow T7 DNA polymerase-dependent expression.
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2.3. Puri¢cation of recombinant PfGR
Plasmid-carrying SG5(DE3) cells were grown in Luria-Bertani me-
dium containing 50 Wg/ml carbenicillin to an apparent OD600 nms 0.5.
PfGR expression was then induced by 1 mM IPTG. After 12 h at
25‡C the cells were harvested by centrifugation. The resulting bacterial
pellet (appr. 7 g) was resuspended in lysing solution (50 mM Tris-HCl,
150 mM NaCl, 10% glycerol, 0.03% Triton X-100, 1 mg/ml lysozyme,
10 WM phenylmethylsulfonyl £uoride, 10 Wg/ml DNase I, pH 7.5) and
subjected to sonication.
After clearing centrifugation, the supernatant was saturated to 80%
with ammonium sulfate and left for 12 h at 4‡C. The resulting pre-
cipitate was collected by centrifugation, and the pellet was dialysed
exhaustively at 4‡C against 25 mM potassium phosphate, 1 mM
EDTA, pH 7.0. The retentate was then applied to a 5 ml 2P,5P-
ADP-Sepharose column equilibrated with the same bu¡er. This col-
umn was washed and eluted as described for authentic PfGR [13].
Fractions with PfGR activity were pooled, and 1 mM GSSG was
added in order to oxidize the NADPH used for eluting the enzyme.
The pool was then concentrated and washed with 25 mM potassium
phosphate, 1 mM EDTA, pH 6.9, or 50 mM sodium phosphate, pH
6.9, respectively, using Vivaspin concentrator units. As judged by
silver-stained SDS-PAGE the resulting protein was s 98% pure
(data not shown).
In order to fully saturate PfGR with its prosthetic group FAD, 1 ml
protein solution (Eox with an absorbance of 0.360 at Vmax;vis = 461 nm
in 50 mM sodium phosphate, pH 6.9) was titrated with 100 WM FAD
in the same bu¡er. 0.5 Wl aliquots were removed after each FAD
addition for measuring the enzyme activity. When more than 0.75
nmol FAD had been added the enzyme activity did not increase
further and the spectrum of the solution indicated the presence of
free FAD. It was concluded that the batch of puri¢ed enzyme con-
tained 2.4% apoprotein, and FAD was supplemented to give a PfGR
solution which contained 100 þ 0.3% holoenzyme, the absorbance at
461 nm being 0.369.
2.4. Steady state kinetics and inhibition studies
Glutathione reductase activity was assayed at 25‡C with 100 WM
NADPH and 1 mM GSSG in assay bu¡er (47 mM potassium phos-
phate, 200 mM KCl, 1 mM EDTA, pH 6.9) according to published
procedures [19]. The enzyme-catalyzed conversion of NADPH to
NADP was followed spectrophotometrically (O at 340 nm = 6.22
mM31 cm31). One enzyme unit is de¢ned as the GSSG-dependent
oxidation of 1 Wmol NADPH per min.
The inhibitory e¡ect of methylene blue on recombinant PfGR, au-
thentic PfGR [13] and human GR [12] was studied as follows. Meth-
ylene blue and NADPH were added ¢rst to the assay bu¡er and the
decrease of absorbance (vA1/vt) was monitored for 1 min. This ac-
counted for the spontaneous reaction of NADPH with methylene blue
which was signi¢cant at drug concentrations above 10 WM. Subse-
quently GR (appr. 10 mU) was added and the ensuing vA2/vt was
followed for another minute. vA2/vt was found not to di¡er appreci-
ably from vA1/vt indicating that GR has negligible methylene blue
reduction activity. The glutathione disul¢de reduction reaction was
started with GSSG and yielded vA3/vt. After correction for dilution,
the glutathione reductase activity was proportional to (vA3/min3
vA2/min). The possibility of irreversible inhibition was tested by in-
cubating PfGR at 2 U/ml (170 nM) for 30 min at 4‡C and 25‡C with
10, 100 or 500 WM methylene blue, and then assaying aliquots for
enzyme activity. These incubations were carried out at pH 6.9 and pH
7.4 in the presence and absence of 100 WM NADPH.
2.5. Absorbance and £uorescence measurements
The O-value at Vmax;vis of recombinant PfGR in the Eox form was
computed on the basis of the amount of FAD separated from the
protein by incubation with 0.2% SDS in 50 mM sodium phosphate
bu¡er, pH 6.9, for 60 min at 45‡C in the dark [20]. From 1 ml
holoenzyme with an absorbance of 0.369 at 461 nm (see Section
2.3) 31.5 nmol FAD was released. This corresponds to an O of 11.7
mM31 cm31 for the holoenzyme. When determining FAD we took
into account that, in the presence of 0.2% SDS, free FAD has a
millimolar absorbance coe⁄cient of 11.4 mM31 cm31 at 448 nm
and that 3% of the released FAD is thermally destroyed during the
incubation at 45‡C.
Absorption spectroscopy of PfGR under anaerobic conditions was
carried out using the methods detailed for E. coli glutathione reduc-
tase [21]. After recording the spectrum of PfGR in oxidized form
(Eox ; 9.5 nmol enzyme subunit in 1 ml 50 mM potassium phosphate,
2 mM EDTA, pH 7.45 at 25‡C), the enzyme was converted to the
EH2 form using sodium borohydride (150 nmol dissolved in 2 ml 0.2
M NaOH) as a reductant. NaBH4 hydrolysis (t1=2 = 20 s at pH 7.45)
did not interfere with the reduction of PfGR which was complete in
less than 1 min. The spectra at pH 6.9 exhibited the same character-
istics as at pH 7.45. However, a 60-fold excess of sodium borohydride
had to be used because of the 7-fold higher hydrolysis rate at pH 6.9
[22].
Fluorescence measurements were conducted according to Mulroo-
ney [23]. For the emission spectra of FAD, both free and protein-
bound, the excitation was set at 380 nm while the observed peak of
relative £uorescence for both was at 540 nm. Tryptophan, both free
and protein-bound, was excited at 295 nm; the emission peaks were at
330 nm and 340 nm, respectively. In addition to this blue shift [24],
the £uorescence of the enzyme’s unique Trp residue was enhanced
2-fold when compared with the free amino acid.
3. Results and discussion
3.1. Expression and puri¢cation of rPfGR
Recently we have characterized the PfGR gene of the P.
falciparum strain K1 (Thailand) [14]. As the gene carries two
introns, RT-PCR on parasitic mRNA from erythrocytic
stages was used to obtain the 5P-end of the open reading
frame. Expecting a solid stem structure of the mRNA, Tth
DNA polymerase was used as this enzyme exhibits reverse
transcriptase activity at 65‡C. By several cloning steps, the
resulting PCR product and the inserts of pG1^pG4 were fused
to gain the complete ORF of PfGR in plasmid pTG. Its insert
was excised and ligated into vector pET22b+, and the result-
ing construct pG11 was transformed into the glutathione re-
ductase-de¢cient E. coli strain SG5(DE3). The expressed pro-
tein, recombinant PfGR, was puri¢ed to homogeneity and
demonstrated high enzymatic activity (Table 1).
3.2. Characterization of recombinant PfGR
Systematic studies on a large malarial protein as a drug
target are hampered by the following di⁄culties. The authen-
tic protein can be isolated only in small amounts from the
parasite and tends to be contaminated with host cell proteins
of similar function. Furthermore, recombinant parasite genes
often resist functional expression in heterologous systems. As
reported here, it was possible to obtain P. falciparum gluta-
thione reductase in good yield, and its enzymic properties
were found to be practically indistinguishable from those of
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Table 1
Isolation procedure for recombinant PfGR from a 1 l culture containing 7 g E. coli SG5(DE3) transformed with pG11
Fraction Volume
(ml)
Total PfGR
(units)
Total protein
(mg)
Spec. activity
(units/mg)
Puri¢cation
(-fold)
Yield
(%)
Bacterial extract 20.0 1650 1120 1.47 1 100
Pellet after 80% (NH4)2SO4 ; dialysed 24.0 1490 402 3.70 2.52 90.3
Eluate from 2P,5P-ADP-Sepharose
(after concentration)
1.0 1160 6.70 173 118 70.3
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the authentic enzyme. Physicochemical studies on rPfGR were
conducted in comparison with the human host enzyme (Table
2). The two enzymes had, for instance, comparable character-
istics when subjected to gel ¢ltration on Superose 12; this
indicates that rPfGR is a homodimeric enzyme. As detailed
in Section 2, the quantitation of rPfGR was based on the
molar absorbance of the £avoenzyme in the Eox form at 461
nm (Table 2). The absorption spectra of rPfGR in the oxi-
dized form Eox and the 2-electron reduced form EH2 (Fig. 1)
exhibit the typical characteristics of the pyridine nucleotide-
disul¢de oxidoreductase family [6]. Table 2 also includes data
on the £uorescence of the £avin and the unique tryptophan
residue of PfGR. These £uorescence properties can be used
for monitoring changes in the protein induced by ligand bind-
ing and by mutations [24].
3.3. Inhibition of PfGR by methylene blue
When 10 WM methylene blue was present in the assay mix-
ture the activity of rPfGR was 60% lower than in the control
assay. This inhibition did not show any time dependence and
was completely reversible by dilution. Also, preincubation of
rPfGR at 2 U/ml (= 0.17 WM) with up to 500 WM methylene
blue ^ in the absence or presence of 100 WM NADPH, at pH
6.9 or pH 7.4 ^ did not lead to irreversible inactivation. Other
inhibitors such as carmustine are known to modify the
NADPH reduced enzyme irreversibly [25].
The Km-values for the substrates NADPH and GSSG were
found to be unchanged in the presence of methylene blue.
Assuming non-competitive inhibition, the Ki-values of meth-
ylene blue were 6.4 ( þ 0.3) WM for the parasite enzyme and
16.1 ( þ 0.8) WM for human GR (Fig. 2).
Methylene blue is an approved drug. Common indications
are septic shock [26] ^ methylene blue appears to inhibit en-
zymes of NO metabolism [27] ^ and certain forms of meth-
emoglobinemia [28]. Against malaria it has been used only on
sporadic occasions [15,16]. At the therapeutic blood concen-
tration of approximately 50 WM, a number of other molecular
targets in P. falciparum such as the heme-polymerization re-
action [29] might be a¡ected. Glutathione reductase is the ¢rst
molecule to be identi¢ed as a target of methylene blue in the
parasite. Taking into account the speci¢c accumulation of
methylene blue in the parasites [16,30], the inhibition of
PfGR (Fig. 2) is likely to contribute signi¢cantly to the cyto-
toxic e¡ects. Consequently the phenothiazine structure of
methylene blue [16] will be included in the lead compounds
for the rational development of therapeutic GR inhibitors
[4,11,31]. Work on the crystallization of the GR-methylene
blue complexes is in progress. Under the conditions used for
analyzing human GR crystals by X-ray di¡raction (0.9 M
ammonium sulfate in assay bu¡er), the apparent Ki-value of
PfGR for methylene blue was found to be 23 WM while the
Km-values for NADPH and GSSG increased to about 100
WM. This suggests that the structures of catalytically compe-
tent PfGR as well as methylene blue-inhibited PfGR can be
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Fig. 1. Absorption spectra of PfGR. The measurements were con-
ducted under anaerobic conditions with 9.6 WM enzyme in 50 mM
potassium phosphate, 2 mM EDTA, pH 7.45 at 25‡C [21]. The sol-
id line represents Eox, the yellow oxidized enzyme species, and the
dotted line EH2, the 2-electron reduced orange-colored enzyme spe-
cies which was obtained from Eox using sodium borohydride. The
spectra of Eox and EH2 at pH 6.9 in 50 mM phosphate-2 mM
EDTA bu¡er show the same characteristics as at pH 7.45 (data not
shown). EH2, possibly complexed with NADPH and carrying gluta-
thione as a mixed disul¢de [33] is the predominant form of gluta-
thione reductase in vivo [7].
Table 2
Comparison of recombinant Plasmodium falciparum GR with human host GR
Protein PfGR Human GR
Mr 114.3 kDa 104.8 kDa
Subunit Mr 57 155 Da [6] 52 395 Da
Prosthetic group FAD FAD
Vmax;vis for Eox 461 nm 463 nm
O at Vmax;vis for Eox 11.7 mM31 cm31 11.3 mM31 cm31
A at 280 nm/A at Vmax;vis for Eox 6.35 6.7
Fluorescence of GR-bound vs. free compound FAD v12-fold quenching v20-fold quenching
W 497, the single Trp of PfGR 2-fold enhancement does not apply
Km for GSSG 83 WM 65 WM
Km for NADPH 8.3 WM 8.5 WM
Activity with NADH/activity with NADPH 6 0.04 0.05
Turnover number 9900 min31 12 600 min31
Speci¢c activity 173 U/mg 240 U/mg
Optimal pH for enzyme activity 6.9^7.2 6.7^6.9
Ki for methylene blue 6.4 WM 16 WM
- in the presence of 0.9 M (NH4)2SO4 23 WM 34 WM
Apart from the Ki for methylene blue, the data for human GR were taken from [7,10^12]. Recombinant PfGR was found not to di¡er in its
enzymic properties from the authentic enzyme. The somewhat lower Km-values, namely 4.8 WM for NADPH and 69 WM for GSSG reported
previously for authentic PfGR [13], could not be reproduced in the present study where more enzyme puri¢ed from P. falciparum was available for
kinetic studies.
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studied by crystallographic methods [10,11]. It will be inter-
esting to see if the drug binds in the intersubunit cavity [10] as
it is the case for most known tricyclic inhibitors of human GR
[11,31,32]. When modelling the amino acid sequence of PfGR
[14] into the structure of human GR [10], only 32% identity
was found for the residues lining this cavity. In conclusion,
structural comparisons of PfGR with human GR, particularly
those distinctions responsible for the di¡erent inhibition by
methylene blue, are expected to serve as an approach to the
development of selective drugs.
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Fig. 2. Inhibition of PfGR and human GR by 10 WM methylene
blue. As shown in the Lineweaver-Burk diagram for GSSG as a
substrate, methylene blue is a non-competitive inhibitor of GR
(open squares, PfGR; open circles, hGR; ¢lled squares and circles,
PfGR and hGR, respectively, in the presence of 10 WM methylene
blue).
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